Kamada (KMDA) - Total Assets
Based on the latest financial reports, Kamada (KMDA) holds total assets worth ILA377.21 Million ILA (≈ $1.01 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check KMDA cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Kamada - Total Assets Trend (2006–2024)
This chart illustrates how Kamada's total assets have evolved over time, based on quarterly financial data. Check Kamada (KMDA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Kamada - Asset Composition Analysis
Current Asset Composition (December 2024)
Kamada's total assets of ILA377.21 Million consist of 49.5% current assets and 50.5% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 21.1% |
| Accounts Receivable | ILA23.20 Million | 6.2% |
| Inventory | ILA78.82 Million | 21.2% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA101.86 Million | 27.4% |
| Goodwill | ILA30.31 Million | 8.1% |
Asset Composition Trend (2006–2024)
This chart illustrates how Kamada's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KMDA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kamada's current assets represent 49.5% of total assets in 2024, an increase from 0.0% in 2006.
- Cash Position: Cash and equivalents constituted 21.1% of total assets in 2024, down from 26.9% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 35.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 27.4% of total assets.
Kamada Competitors by Total Assets
Key competitors of Kamada based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Kamada - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.03 | 4.84 | 7.13 |
| Quick Ratio | 2.24 | 2.73 | 5.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA144.90 Million | ILA130.41 Million | ILA152.95 Million |
Kamada - Advanced Valuation Insights
This section examines the relationship between Kamada's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.95 |
| Latest Market Cap to Assets Ratio | 0.89 |
| Asset Growth Rate (YoY) | 4.9% |
| Total Assets | ILA372.25 Million |
| Market Capitalization | $331.09 Million USD |
Valuation Analysis
Near Book Valuation: The market values Kamada's assets close to their book value (0.89x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Kamada's assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Kamada (2006–2024)
The table below shows the annual total assets of Kamada from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA372.25 Million ≈ $998.00K |
+4.89% |
| 2023-12-31 | ILA354.91 Million ≈ $951.49K |
+10.09% |
| 2022-12-31 | ILA322.38 Million ≈ $864.29K |
+1.16% |
| 2021-12-31 | ILA318.67 Million ≈ $854.34K |
+51.27% |
| 2020-12-31 | ILA210.66 Million ≈ $564.79K |
+21.21% |
| 2019-12-31 | ILA173.80 Million ≈ $465.94K |
+25.83% |
| 2018-12-31 | ILA138.12 Million ≈ $370.28K |
+13.11% |
| 2017-12-31 | ILA122.11 Million ≈ $327.37K |
+22.48% |
| 2016-12-31 | ILA99.70 Million ≈ $267.28K |
-2.25% |
| 2015-12-31 | ILA101.99 Million ≈ $273.44K |
-14.74% |
| 2014-12-31 | ILA119.62 Million ≈ $320.69K |
-14.18% |
| 2013-12-31 | ILA139.38 Million ≈ $373.67K |
+56.41% |
| 2012-12-31 | ILA89.11 Million ≈ $238.91K |
+4.29% |
| 2011-12-31 | ILA85.45 Million ≈ $229.09K |
-6.63% |
| 2010-12-31 | ILA91.52 Million ≈ $245.37K |
+45.48% |
| 2009-12-31 | ILA62.91 Million ≈ $168.66K |
+49.57% |
| 2008-12-31 | ILA42.06 Million ≈ $112.77K |
-66.82% |
| 2007-12-31 | ILA126.76 Million ≈ $339.83K |
-5.70% |
| 2006-12-31 | ILA134.42 Million ≈ $360.39K |
-- |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more